Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial

Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial

Abstract Background A substantial proportion of rheumatoid arthritis (RA) patients discontinues treatment with tumour necrosis factor inhibitors (TNFi) due to inefficacy or intolerance. After the failure of treatment with a TNFi, treatment can be switched to another TNFi or a bDMARD with a different...

Full description

Bibliographic Details
Main Authors: Maike H. M. Wientjes, Sadaf Atiqi, Gerrit Jan Wolbink, Michael T. Nurmohamed, Maarten Boers, Theo Rispens, Annick de Vries, Ronald F. van Vollenhoven, Bart J. F. van den Bemt, Alfons A. den Broeder
Format: Article
Language:English
Published: BMC 2021-06-01
Series:Trials
Subjects:
Rheumatoid arthritis
Adalimumab
Anti-TNF
Therapeutic drug monitoring
Drug concentration
Switching
Online Access:https://doi.org/10.1186/s13063-021-05358-7

Internet

https://doi.org/10.1186/s13063-021-05358-7

Similar Items